NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam.
Alnylam has filed its RNAi therapy patisiran with the FDA for the rare disease hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy. Datamonitor pointed out that patisiran ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback